Otsuka Pharmaceutical Co. Ltd. has set its sights on a new digital tablet of Abilify (aripiprazole) to extend the life of the brand that is now facing generic competition. The company announced Sept. 10 that a combination of the atypical antipsychotic embedded with an ingestible sensor developed by partner Proteus Digital Health Inc. has been accepted for filing by FDA. The review deadline is for April 2016.
The combination represents the first time such a pill has been submitted to FDA for review, according to the company....